Effects of a Resurgence in COVID-19 Cases on Future Pharmaceutical Business Planning

WHITE PAPER

WHITE PAPER

Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning

Fears have arisen regarding a resurgence in COVID-19 cases. Numerous factors could be contributing to a resurgence in COVID-19 cases. Some suggest it is because more tests are being conducted than in prior months while others attribute the increase to more testing as well as other factors, including the effects from local economies reopening, people failing to maintain social distancing and wear protective masks, and the recent mass protests and disturbances in many cities in reaction to the death of George Floyd. Health experts are not sure what is causing a spike in infections occurring in certain areas around the country. The recent resurgence in COVID-19 cases in 33 states have health experts concerned and will undoubtedly cause challenges as states try to reopen their economies. Federal Reserve Chairman Jerome Powell noted continued challenges and uncertainty regarding the US economic recovery from the worst recession since the Great Depression in a June 10, 2020 press conference. Financial markets negatively reacted to this news on June 11, 2020 with averages across the board significantly falling: DJIA (-6.9%), S&P 500 (-5.9%), and NASDAQ (-5.3%). This white paper analyzes the most likely scenario for a US economic recovery from this COVID-19 induced recession and what the resurgence in COVID-19 cases means for future pharmaceutical business planning.

Contact us at insights@axtria.com with any questions.

Get Your Copy!

Suggested Blogs

Let Us Show You What Axtria’s 

Solutions Can Do For You